Radiotheranostics in Oncology – Current Challenges and Emerging Opportunities in 2025
Learn how cancer radiotheranostics transforms oncology by using imaging to target treatments directly at specific cancer cells.
Learn how cancer radiotheranostics transforms oncology by using imaging to target treatments directly at specific cancer cells.
Discover the journey of terbium radionuclides from research to clinical application, focusing on their theranostic capabilities.
Learn how radiotheranostics in cancer care combines imaging and therapy for better outcomes in advanced malignancies.
Find out how radiotheranostics medicine is transforming cancer therapy by merging diagnostics with targeted radionuclide therapy.
Learn about theranostics and why it differs from radiotheranostics. Tailor treatments with advanced diagnostics.
Radioactive isotopes emit targeted radiation that effectively destroys cancer cells while minimising harm to healthy tissues.
Yttrium-90 Tabituximab barzuxetan is a radiolabelled drug designed for targeted synovial sarcoma treatment.
Yttrium-90 OPS201, a receptor antagonist, delivers targeted beta radiation for effective neuroendocrine tumour therapy and research.
Zevalin therapy combines monoclonal antibody targeting with Yttrium-90 radiation to treat non-Hodgkin’s lymphoma effectively.
Ferritarg therapy targets acidic ferritin in cancer cells, offering precision treatment for refractory Hodgkin’s disease and other malignancies.
Yttrium-90 FAPi-46 targets fibroblast activation protein, providing effective radiotherapy for tumours and fibrotic diseases.
Yttrium-90 FAPi-04 is a promising radiotherapeutic targeting fibroblast activation protein in cancer-associated fibroblasts effectively.
Yttrium-90 Epratuzumab Tetraxetan enhances Non-Hodgkin Lymphoma treatment through targeted radioimmunotherapy and durable responses.
Yttrium-90 Edotreotide delivers targeted beta radiation therapy to somatostatin receptor-positive neuroendocrine tumours with precision.
Yttrium-90 DOTA-FF-21101 targets P-Cadherin in solid tumours, delivering beta radiation for precise cancer treatment.
Yttrium-90 Besilesomab targets CD66-expressing cells, providing precise beta radiation therapy for systemic amyloid light chain amyloidosis.
Yttrium-90 Anditixafortide targets CXCR4-expressing tumours, delivering therapeutic β– radiation precisely, improving treatment outcomes significantly.
Thorium-227 Anetumab Corixetan delivers targeted alpha radiation, effectively treating mesothelin-expressing tumours while sparing healthy tissues.
Terbium-161 PSMA-I&T combines precise PSMA targeting with beta and Auger emissions, revolutionising prostate cancer treatment efficacy.
Tin-117m DTPA offers innovative treatment options for bone metastases, combining therapeutic efficacy with minimal collateral tissue damage.
Tin-117m DOTA-Annexin V revolutionises medicine by simultaneously imaging and treating vulnerable plaques, cancers, and neuroinflammation.
Samarium-153 DOTMP, a promising radiopharmaceutical, targets bone metastases effectively while allowing precise imaging for clinical monitoring.
Rhenium-188 SSS/Lipiodol combines targeted delivery with beta radiation, offering hope for advanced hepatocellular carcinoma patients.
Rhenium-188 Colloidal Sulfide provides targeted radiation therapy, reducing joint inflammation and pain in large rheumatoid arthritis-affected joints.
Rhenium-188 HDD/Lipiodol therapy offers targeted radiopharmaceutical treatment for advanced hepatocellular carcinoma with portal vein thrombosis.
Rhenium-188 P2045 is a peptide-based radiopharmaceutical targeting somatostatin receptors for treating neuroendocrine and pancreatic cancers.
Rhenium-188 Etidronate effectively targets metastatic bone lesions, delivering therapeutic beta radiation while reducing associated pain.
Lead-203 DOTA-VMT-MCR1 binds MC1R with high specificity, facilitating targeted imaging and image-guided therapy for metastatic melanoma patients.
Lead-212 VMT-α-NET offers advanced targeted therapy for neuroendocrine tumours by harnessing precise alpha-particle radiation.
Lead-212 DOTAMTATE targets somatostatin receptors in neuroendocrine tumours, delivering potent alpha-emission therapy with minimal off-target toxicity.